ISSUE 1529
| The full issue is available to subscribers | Subscriber Login |
The FDA has approved Xultophy 100/3.6 (Novo Nordisk), a fixed-ratio combination of insulin degludec and the GLP-1 (glucagon-like peptide-1) receptor agonist liraglutide, for once-daily treatment of adults with type 2 diabetes inadequately controlled on basal insulin (<50 units daily) or liraglutide (≤1.8 mg daily).
Soliqua 100/33, a long-acting insulin/GLP-1 receptor agonist combination that contains insulin glargine (Lantus, and others) and lixisenatide (Adlyxin), has also recently become available in the US.1
GLP-1 RECEPTOR AGONISTS — GLP-1 receptor agonists lower glucose levels by potentiating glucose-dependent insulin secretion, suppressing postprandial glucagon secretion, slowing gastric emptying, and promoting satiety. They lower glycated hemoglobin (A1C) by about 1-1.5%, have been associated with weight loss of 1.5-2.8 kg,
... more- Lixisenatide for type 2 diabetes. Med Lett Drugs Ther 2017; 59:19.
- Drugs for type 2 diabetes. Med Lett Drugs Ther 2017; 59:9.
- SP Marso et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375:311.
- JFE Mann et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 2017; 377:839.
- SC Gough et al. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. Lancet Diabetes Endocrinol 2014; 2:885.
- JB Buse et al. Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira). Diabetes Care 2014; 37:2926.
- S Linjawi et al. The efficacy of IDegLira (insulin degludec/liraglutide combination) in adults with type 2 diabetes inadequately controlled with a GLP-1 receptor agonist and oral therapy: DUAL III randomized clinical trial. Diabetes Ther 2017; 8:101.
Would you like to read the rest of this issue? Gain access below.
- Print version published and mailed biweekly (26 issues/year)
- Immediate Online access to current issue and archives from 1988 to the present
- Mobile access to our mobile site and free apps for iOS, Android and Kindle
- FREE online per issue CME/CE
